Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan;40(1):136-154.
doi: 10.2337/dc16-2042.

Diabetic Neuropathy: A Position Statement by the American Diabetes Association

Rodica Pop-Busui  1 , Andrew J M Boulton  2 , Eva L Feldman  3 , Vera Bril  4 , Roy Freeman  5 , Rayaz A Malik  6 , Jay M Sosenko  7 , Dan Ziegler  8
Affiliations
Review

Diabetic Neuropathy: A Position Statement by the American Diabetes Association

Rodica Pop-Busui et al. Diabetes Care. 2017 Jan.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanisms of diabetic neuropathy. Factors linked to type 1 diabetes (yellow), type 2 diabetes (blue), and both (green) cause DNA damage, endoplasmic reticulum stress, mitochondrial dysfunction, cellular injury, and irreversible damage. The relative importance of the pathways in this network will vary with cell type, disease profile, and time. ER, endoplasmic reticulum; FFA, free fatty acids; PI3-K, phosphatidylinositol-3 kinase; RNS, reactive nitrogen species; ROS, reactive oxygen species. Adapted and reprinted from Callaghan et al. (20), with permission from Elsevier.
Figure 2
Figure 2
Algorithm for management of the patient with pain because of DSPN. AE, adverse events.*Pregabalin is FDA approved for painful DSPN, whereas gabapentin is not. Pharmacokinetic profile, spectrum of AEs, drug interactions, comorbidities, and costs to be considered in selecting the agent of choice. **Duloxetine is FDA approved for painful DSPN, whereas venlafaxine is not. Pharmacokinetic profile, spectrum of AEs, drug interactions, comorbidities, and costs to be considered in selecting the agent of choice. #None is FDA approved for painful DSPN. Spectrum of AEs, drug interactions, and comorbidities need be considered if selecting these agents.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep 2014;14:473. - PMC - PubMed
    1. Callaghan BC, Kerber KA, Lisabeth LL, et al. . Role of neurologists and diagnostic tests on the management of distal symmetric polyneuropathy. JAMA Neurol 2014;71:1143–1149 - PMC - PubMed
    1. Dyck PJ, Albers JW, Andersen H, et al. .; Toronto Expert Panel on Diabetic Neuropathy . Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev 2011;27:620–628 - PubMed
    1. Malik RA, Veves A, Tesfaye S, et al. .; Toronto Consensus Panel on Diabetic Neuropathy . Small fibre neuropathy: role in the diagnosis of diabetic sensorimotor polyneuropathy. Diabetes Metab Res Rev 2011;27:678–684 - PubMed
    1. Smith AG, Singleton JR. Diabetic neuropathy. Continuum (Minneap Minn) 2012;18:60–84 - PubMed